In the news | 1st March 2022
Advances in Biologics Require Advances in Data Management
Throughout the past few years, there’s been a clear trend in the makeup of approvals, with biologics representing a growing percentage. But even within biologics, newer technologies like mRNA, cell, and gene therapies are gaining ground. The approvals are not one-off events, but evidence of an exciting long-term trend. Learn more from Christian Marcazzo, General Manager at IDBS, in his article published in Drug Development & Discovery.
Putting Your CMC Ontology to Work | Pistoia Alliance 2026
Join IDBS at the Pistoia Alliance conference as Ken Forman explores how organizations can transform a documented CMC ontology into a GxP-qualified operational framework. Learn how linking ontology to experimental data enables structured, submission-ready information, improving data exchange, regulatory compliance, and the efficiency of CMC processes.
CMC regulatory submissions: Why knowledge continuity matters
Biopharma organizations have invested heavily in managing CMC data, yet many continue to face a less visible challenge: preserving the knowledge behind critical development decisions. As products progress through development and teams evolve, maintaining scientific context can become just as important as maintaining the underlying data.
i3 2027 registration
IDBS i3 2027 brings together life sciences leaders to explore how connected data, AI, and modern informatics are transforming scientific innovation. Join us in Woking for 1.5 days of customer stories, expert insights, interactive sessions, and networking opportunities.
i3 Japan 2026
Join us at i3 Japan and be part of the conversation shaping the future of BioPharma in Japan. Hear real-world case studies from IDBS users and gain insights from IDBS experts on our solutions.
